Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Value of Tumour-Infiltrating Immune Cells in Predicting Response to Intravesical Bcg in Patients With Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis Publisher Pubmed



Kardoust Parizi M1, 2 ; Shariat SF2, 3, 4, 5, 6, 7, 8 ; Margulis V3 ; Mori K2, 9 ; Lotan Y3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Urology, Medical University of Vienna, Vienna, Austria
  3. 3. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States
  4. 4. Department of Urology, Weill Cornell Medical College, New York, NY, United States
  5. 5. Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic
  6. 6. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
  7. 7. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
  8. 8. European Association of Urology Research Foundation, Arnhem, Netherlands
  9. 9. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan

Source: BJU International Published:2021


Abstract

Objective: To investigate the predictive value of tumour-infiltrating immune cells (TIICs) on oncological outcomes and response to BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC). Materials and Methods: A systematic review and meta-analysis was performed using PubMed, Scopus and the Cochrane Library in July 2020 to identify relevant studies according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The pooled recurrence-free survival (RFS) rate was calculated using a fixed-effect model. Results: We retrieved 15 studies (including 791 patients) evaluating the effect of TIICs on oncological outcomes in patients with NMIBC treated with intravesical BCG. TIICs were reported to be a significant predictor of oncological outcomes and response to BCG treatment in 10 studies. Tumour-associated macrophages were associated with worse RFS (pooled hazard ratio 2.30, 95% confidence interval 1.64–3.22). Conclusions: Based on these data, TIICs are significant predictors of RFS and response to BCG treatment in patients with NMIBC; therefore, incorporation of TIICs into risk stratification models may help patients and physicians in the clinical decision-making process in order to achieve the maximum possible benefit from BCG treatment. © 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd
Experts (# of related papers)
Other Related Docs
24. Improving Adverse Drug Event Reporting by Health Care Professionals, Cochrane Database of Systematic Reviews (2017)
27. Improving Adverse Drug Event Reporting by Healthcare Professionals, Cochrane Database of Systematic Reviews (2024)